Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs ACT 541468 (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 13 Jul 2017 Status changed from active, no longer recruiting to completed.
- 05 Jul 2017 Planned End Date changed from 30 Aug 2017 to 29 Aug 2017.
- 08 Jun 2017 Status changed from recruiting to active, no longer recruiting.